Gene therapy for cardiac arrhythmias: a dream soon to come true?
Alternatively, excitement and frustration have been generated from the literature reports of gene therapy for treatment and potential cure of cardiac diseases. The time since the first literature report of in vivo myocardial gene transfer is more than 15 years, and the time since the first report of gene therapy for a cardiac arrhythmia is six years. Clinical trials, let alone clinical usage, of these promising therapies have not yet started. This article reviews the current state of the art for arrhythmia gene therapy, including the literature reports of antiarrhythmic studies and of problems within the field. Gene transfer continues to be a promising technology, but patience is required as these problems are solved and the therapies make their way through the preclinical and clinical testing process.
Donahue
J Kevin
JK
Heart and Vascular Research Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44116, USA. kdonahue@metrohealth.org
D001145:Arrhythmias, Cardiac / Q000235:genetics* / Q000628:therapy*; D018390:Gene Targeting / Q000379:methods* / Q000639:trends*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends*; D006801:Humans